Predicting the Risk of Recurrence After Surgery for Prostate Cancer
Am Fam Physician. 2005 Dec 15;72(12):2511-2512.
What is the risk of recurrence in a patient with prostate cancer who undergoes radical prostatectomy?
A previous Point-of-Care Guide1 identified a clinical decision rule that estimates the likelihood of an abnormal biopsy for prostate cancer. One of the next questions facing the patient and his physician is the likelihood of recurrence after surgery.
Several clinical decision rules have addressed this question. One is the University of California, San Francisco Cancer of the Prostate Risk Assessment score, which was developed based on 1,439 men who underwent prostatectomy.2 Recurrence occurred in 15 percent of patients and was defined as a prostate-specific antigen (PSA) of 0.2 ng per mL or greater on two consecutive occasions or the need for a second cancer treatment at least six months after surgery. The score used the preoperative PSA, Gleason grade, tumor stage, percentage of positive biopsies, and patient age. Each variable was assigned points, and the point total corresponded to a five-year recurrence rate (e.g., 5.6 percent for a score of 0, 17 percent for a score of 4, and 78 percent for a score of 7 or higher). Although promising, this score has not been prospectively validated.
The most widely validated score was developed by Kattan and colleagues.3 It was developed based on a group of 983 men with clinically localized prostate cancer (stages T1a through T3a) who underwent radical prostatectomy between 1983 and 1996. The score uses the PSA, clinical stage, and Gleason grade to predict recurrence, which is defined as a postoperative serum PSA of 0.4 ng per mL or higher, clinical evidence of recurrence, or the need for subsequent treatment. The rule was initially validated in a group of 168 patients treated by the same group of surgeons. It also has been validated in a group of 1,033 patients in Europe4 and in a large community-based cohort of 1,701 patients in the United States.5 In the latter group, 24 percent experienced recurrence. The accuracy of the Kattan score was measured using a concordance index (a statistical measure of agreement from 0 to 1 in which 1 is perfect agreement and 0.5 is no better than chance). The concordance index for the Kattan nomogram was 0.68 in the large community validation study. The Kattan nomogram also was prospectively validated in a group of 331 black men, with a concordance index of 0.78.6
A score developed by D'Amico and colleagues included not only men who had prostatectomy but also those who underwent external beam radiation.7 However, the rule only predicted two-year recurrence and was less accurate than the Kattan rule used in the European validation study.4
The Kattan nomogram is shown in Figure 1. It is also available as a free handheld computer application at http://www.nomograms.org. The electronic version includes the estimated recurrence risk following radiotherapy.8 Although this nomogram provides useful guidance for patients and their physicians, it is important that they understand that the nomogram is not perfectly accurate and should not be the only tool used in decision making about cancer treatment and follow-up. Other factors such as the patient's age, how they feel about the risk of impotence and incontinence, and comorbidities also must be considered. Also, this nomogram is only applicable for a man who has already selected radical prostatectomy as a treatment for his prostate cancer, because that is the group in which it was validated.
Applying the Evidence
A patient with an abnormal digital rectal examination undergoes a prostate biopsy. His PSA score is 2.9, his Gleason grade is 3 + 3 = 6, and his tumor stage is 2a. What is the likelihood that he will remain free of cancer recurrence five years after surgery?
Answer: The physician consults the Kattan nomogram (Figure 1) and assigns 33 points for the PSA of 2.9, 9 points for the 2a tumor stage, and 25 for the Gleason grade of 6. The total score is 67 points, which predicts a 91 percent chance that he will remain recurrence free for five years.
REFERENCESshow all references
1. Ebell MH. Predicting the risk of prostate cancer on biopsy. Am Fam Physician. 2005;72:1091–2....
2. Cooperberg MR, Pasta DJ, Elkin EP, Litwin MS, Latini DM, Du Chane J, et al. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy. J Urol. 2005;173:1938–42.
3. Kattan MW, Eastham JA, Stapleton AM, Wheeler TM, Scardino PT. A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. J Natl Cancer Inst. 1998;90:766–71.
4. Graefen M, Karakiewicz PI, Cagiannos I, Hammerer PG, Haese A, Palisaar J, et al. A validation of two preoperative nomograms predicting recurrence following radical prostatectomy in a cohort of European men. Urol Oncol. 2002;7:141–6.
5. Greene KL, Meng MV, Elkin EP, Cooperberg MR, Pasta DJ, Kattan MW, et al. Validation of the Kattan preoperative nomogram for prostate cancer recurrence using a community based cohort: results from cancer of the prostate strategic urological research endeavor (CaPSURE). J Urol. 2004;171(6 pt 1)2255–9.
6. Bianco FJ Jr, Kattan MW, Scardino PT, Powell IJ, Pontes JE, Wood DP Jr. Radical prostatectomy nomograms in black American men: accuracy and applicability. J Urol. 2003;170:73–6.
7. D'Amico AV, Whittington R, Malkowicz SB, Fondurulia J, Chen MH, Kaplan I, et al. Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol. 1999;17:168–72.
8. Kattan MW, Zelefsky MJ, Kupelian PA, Scardino PT, Fuks Z, Leibel SA. Pretreatment nomogram for predicting the outcome of three-dimensional conformal radiotherapy in prostate cancer. J Clin Oncol. 2000;18:3352–9.
This guide is one in a series that offers evidence-based tools to assist family physicians in improving their decision making at the point of care.
Copyright © 2005 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact firstname.lastname@example.org for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
May 15, 2021
Access the latest issue of American Family Physician